Literature DB >> 15765925

Changes in the pattern of respiratory diseases necessitating hospitalization of HIV-infected patients since the advent of highly active antiretroviral therapy.

Véronique Dufour1, Jacques Cadranel, Marie Wislez, Armelle Lavole, Emmanuel Bergot, Antoine Parrot, Pierre Rufat, Charles Mayaud.   

Abstract

The incidence rates of opportunistic diseases, hospital admission and death have fallen markedly since the advent of highly active antiretroviral therapy (HAART). We examined the impact of HAART on the pattern of HIV-related respiratory diseases necessitating hospitalization. We retrospectively compared the numbers and etiologies of respiratory diseases diagnosed in HIV-infected patients hospitalized in the chest department of a Paris university hospital during the three years preceding widespread prescription of HAART in France (era 1, starting in July 1993) and the first three years of widespread HAART prescription (era 2, starting in July 1996). Respectively, 207 and 119 HIV-infected patients were admitted for respiratory disease in era 1 and era 2. Only 31.1% of patients admitted during era 2 were receiving HAART. Pulmonary opportunistic infections other than Pneumocystis carinii pneumonia (PCP) (p = 0.0008) and exacerbations of chronic bronchial disease due to gram-negative bacilli (p = 0.04) virtually disappeared in era 2. In contrast, PCP, bacterial pneumonia, tuberculosis, pulmonary Kaposi's sarcoma and pulmonary non-Hodgkin lymphoma showed only a twofold decrease in era 2, while lung cancer was more frequent (p = 0.004). The frequency of severe respiratory diseases necessitating hospitalization of HIV-infected patients has fallen since the advent of HAART, and their etiologic distribution has changed.

Entities:  

Mesh:

Year:  2004        PMID: 15765925     DOI: 10.1007/s00408-004-2513-4

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  33 in total

1.  1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA).

Authors: 
Journal:  MMWR Recomm Rep       Date:  1999-08-20

2.  The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs.

Authors:  D M Forrest; E Seminari; R S Hogg; B Yip; J Raboud; L Lawson; P Phillips; M T Schechter; M V O'Shaughnessy; J S Montaner
Journal:  Clin Infect Dis       Date:  1998-12       Impact factor: 9.079

3.  Impact of combination therapy for HIV infection on inpatient census.

Authors:  R A Torres; M Barr
Journal:  N Engl J Med       Date:  1997-05-22       Impact factor: 91.245

4.  Subacute hypersensitivity pneumonitis in an HIV infected patient receiving antiretroviral therapy.

Authors:  A M Morris; S Nishimura; L Huang
Journal:  Thorax       Date:  2000-07       Impact factor: 9.139

Review 5.  Noninfectious pulmonary complications of infection with the human immunodeficiency virus.

Authors:  D A White; R A Matthay
Journal:  Am Rev Respir Dis       Date:  1989-12

6.  Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy.

Authors:  H R Brodt; B S Kamps; P Gute; B Knupp; S Staszewski; E B Helm
Journal:  AIDS       Date:  1997-11-15       Impact factor: 4.177

7.  Cytomegalovirus as a primary pulmonary pathogen in AIDS.

Authors:  A B Waxman; S J Goldie; H Brett-Smith; R A Matthay
Journal:  Chest       Date:  1997-01       Impact factor: 9.410

8.  Changing patterns of respiratory disease in HIV positive patients in a referral centre in the United Kingdom between 1986-7 and 1990-1.

Authors:  A D Pitkin; A D Grant; N M Foley; R F Miller
Journal:  Thorax       Date:  1993-03       Impact factor: 9.139

9.  Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

Authors:  A Mocroft; S Vella; T L Benfield; A Chiesi; V Miller; P Gargalianos; A d'Arminio Monforte; I Yust; J N Bruun; A N Phillips; J D Lundgren
Journal:  Lancet       Date:  1998-11-28       Impact factor: 79.321

Review 10.  Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus.

Authors:  R J Simonds; W T Hughes; J Feinberg; T R Navin
Journal:  Clin Infect Dis       Date:  1995-08       Impact factor: 9.079

View more
  7 in total

Review 1.  Management of patients with HIV in the intensive care unit.

Authors:  Henry Masur
Journal:  Proc Am Thorac Soc       Date:  2006

Review 2.  Lung cancer in HIV infected patients: facts, questions and challenges.

Authors:  J Cadranel; D Garfield; A Lavolé; M Wislez; B Milleron; C Mayaud
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

3.  Giant cell lung carcinoma in a man with acquired immunodeficiency syndrome.

Authors:  Takahide Kodama; Kunihiko Miyazaki; Hiroaki Satoh; Shigemi Hitomi; Morio Ohtsuka
Journal:  Med Oncol       Date:  2008-10-21       Impact factor: 3.064

4.  Cholesterol as a Mediator of Alcohol-Induced Risks for Respiratory Disease Hospitalizations among People Living With HIV.

Authors:  María José Míguez; Rhonda Rosenberg; Ximena Burbano; Robert Malow
Journal:  J AIDS Clin Res       Date:  2011-10-21

5.  The impact of HAART on the respiratory complications of HIV infection: longitudinal trends in the MACS and WIHS cohorts.

Authors:  Matthew R Gingo; G K Balasubramani; Lawrence Kingsley; Charles R Rinaldo; Christine B Alden; Roger Detels; Ruth M Greenblatt; Nancy A Hessol; Susan Holman; Laurence Huang; Eric C Kleerup; John Phair; Sarah H Sutton; Eric C Seaberg; Joseph B Margolick; Stephen R Wisniewski; Alison Morris
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

6.  Bronchopulmonary Kaposi's sarcoma.

Authors:  Nada Bashar; Nicholas Innes; Julian Orrell
Journal:  Respir Med Case Rep       Date:  2015-05-07

7.  Pulmonary Toxoplasmosis Diagnosed on Transbronchial Lung Biopsy in a Mechanically Ventilated Patient.

Authors:  Delyse Garg; Nikhil Madan; Omar Qaqish; Sandhya Nagarakanti; Vipul Patel
Journal:  Case Rep Infect Dis       Date:  2020-02-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.